JLE

European Journal of Dermatology

MENU

Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study Volume 31, numéro 5, September-October 2021

  • [1] Campanati A., Orciani M., Consales V. Characterization and profiling of immunomodulatory genes in resident mesenchymal stem cells reflect the Th1-Th17/Th2 imbalance of psoriasis. Arch Dermatol Res. 2014;306:915-920.
  • [2] Hawkes J.E., Chan T.C., Krueger J.G. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140:645-653.
  • [3] Radi G., Campanati A., Diotallevi F., Bianchelli T., Offidani A. Novel therapeutic approaches and targets for treatment of psoriasis. Curr Pharm Biotechnol. 2020;22:7-31.
  • [4] Conrad C., Gilliet M. Psoriasis: from pathogenesis to targeted therapies. Clin Rev Allergy Immunol. 2018;54:102-113.
  • [5] Ogawa E., Sato Y., Minagawa A., Okuyama R. Pathogenesis of psoriasis and development of treatment. J Dermatol. 2018;45:264-272.
  • [6] Albanesi C. Immunology of psoriasis. In: Rich R.R., eds. Clinical immunology: principles and practice. Amsterdam, Netherlands: Elsevier Inc; 2012775-781.
  • [7] Campanati A., Molinelli E., Brisigotti V., Offidani A. Biologic therapy in psoriasis (part i): efficacy and safety of tumor necrosis factor- alpha inhibitors. Curr Pharm Biotechnol. 2017;18:945-963.
  • [8] Diotallevi F., Campanati A., Radi G., Molinelli E., Offidani A. Ixekizumab for treatment of moderate to severe plaque psoriasis: real world clinical experience. G Ital Dermatol Venereol. 2018;155:739-743.
  • [9] Molinelli E., Campanati A., Brisigotti V., Offidani A. Biologic therapy in psoriasis (part ii): efficacy and safety of new treatment targeting IL23/IL-17 pathways. Curr Pharm Biotechnol. 2017;18:964-978.
  • [10] Borghi A., Corazza M., Bertoldi A.M., Caroppo F., Virgili A. Low-dose acitretin in treatment of plaque-type psoriasis: descriptive study of efficacy and safety. Acta Derm Venereol. 2015;95:332-336.
  • [11] Jaleel T., Elmets C., Weinkle A., Kassira S., Elewski B. Secukinumab (AIN-457) for the treatment of psoriasis. Expert Rev Clin Pharmacol. 2016;9:187-202.
  • [12] Baeten D., Sieper J., Braun J. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534-2548.
  • [13] Bissonnette R., Luger T., Thaci D. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE extension study). J Eur Acad Dermatol Venereol. 2018;32:1507-1514.
  • [14] Blauvelt A., Reich K., Tsai T.F. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76:60-9.e9.
  • [15] Langley R.G., Elewski B.E., Lebwohl M. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 2014;371:326-338.
  • [16] McInnes I.B., Mease P.J., Kirkham B. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 2014;371:326-338.
  • [17] Thaci D., Blauvelt A., Reich K. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400-409.
  • [18] Mrowietz U., Reich K. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400-409.
  • [19] Gottlieb A.B., Merola J.F., Chen R., Levi E., Duffin K.C. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2017;74:1178-1180.
  • [20] Hsu S., Papp K.A., Lebwohl M.G. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148:95-102.
  • [21] Callis Duffin K., Papp K.A., Bagel J., Levi E., Chen R., Gottlieb A.B. Evaluation of the physician global assessment and body surface area composite tool for assessing psoriasis response to apremilast therapy: results from ESTEEM 1 and ESTEEM 2. J Drugs Dermatol. 2017;16:147-153.
  • [22] Gottlieb A.B., Germino R., Herrera V., Meng X., Merola J.F. Exploration of the Product of the 5-point investigator's global assessment and body surface area (IGA x BSA) as a practical minimal disease activity goal in patients with moderate-to-severe psoriasis. Dermatology. 2019;235:348-354.
  • [23] Costanzo A., Bianchi L., Flori M.L. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol. 2018;179:1072-1080.
  • [24] Papini M., Cusano F., Romanelli M. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study. Br J Dermatol. 2019;181:413-414.
  • [25] Taylor W., Gladman D., Helliwell P. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665-2673.
  • [26] Callis Duffin K., Gottlieb A.B. Outcome measures for psoriasis severity: a report from the GRAPPA 2012 annual meeting. J Rheumatol. 2013;40:1423-1424.
  • [27] Gottlieb A.B., Armstrong A.W. Psoriasis outcome measures: a report from the GRAPPA 2012 annual meeting. J Rheumatol. 2013;40:1428-1433.
  • [28] Mattei P.L., Corey K.C., Kimball A.B. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28:333-337.
  • [29] Langley R.G., Feldman S.R., Nyirady J., van de Kerkhof P., Papavassilis C. The 5-point Investigator's Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26:23-31.
  • [30] Kreft S., Kreft M., Resman A., Marko P., Kreft K.Z. Computer-aided measurement of psoriatic lesion area in a multicenter clinical trial – comparison to physician's estimations. J Dermatol Sci. 2006;44:21-27.
  • [31] Long C.C., Finlay A.Y., Averill R.W. The rule of hand: 4 hand areas = 2 FTU = 1 g. Arch Dermatol. 1992;128:1129-1130.
  • [32] Ramsay B., Lawrence C.M. Measurement of involved surface area in patients with psoriasis. Br J Dermatol. 1991;124:565-570.
  • [33] Savolainen L., Kontinen J., Alatalo E., Roning J., Oikarinen A. Comparison of actual psoriasis surface area and the psoriasis area and severity index by the human eye and machine vision methods in following the treatment of psoriasis. Acta Derm Venereol. 1998;78:466-467.
  • [34] Savolainen L., Kontinen J., Roning J., Oikarinen A. Application of machine vision to assess involved surface in patients with psoriasis. Br J Dermatol. 1997;137:395-400.
  • [35] Thomas C.L., Finlay A.Y. The ’handprint’ approximates to 1% of the total body surface area whereas the ’palm minus the fingers’ does not. Br J Dermatol. 2007;157:1080-1081.
  • [36] Finlay A.Y., Khan G.K. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-216.
  • [37] Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-370.
  • [38] Youden W.J. Index for rating diagnostic tests. Cancer. 1950;3:32-35.
  • [39] Rendon A., Schakel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20:1475.
  • [40] Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26:3-11.
  • [41] Giang J., Seelen M.A.J., van Doorn M.B.A., Rissmann R., Prens E.P., Damman J. Complement activation in inflammatory skin diseases. Front Immunol. 2018;9:639.
  • [42] Ricklin D., Lambris J.D. Therapeutic control of complement activation at the level of the central component C3. Immunobiology. 2016;221:740-746.
  • [43] Bai F., Zheng W., Dong Y. Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget. 2018;9:1266-1278.
  • [44] Kerschbaumer A, Fenzl K, Weber M, et al. Serum complement C3 component as a potential disease activity marker in psoriatic arthritis [abstract]. Arthritis Rheumatol 2016; 68. Available from: https://acrabstracts.org/abstract/serum-complement-c3-component-as-a-potential-disease-activity-marker-in-psoriatic-arthritis/.[accessed on 12 september 2019].
  • [45] Reindl J., Pesek J., Kruger T. Proteomic biomarkers for psoriasis and psoriasis arthritis. J Proteomics. 2016;140:55-61.
  • [46] Dattilo G., Imbalzano E., Casale M. Psoriasis and cardiovascular risk: correlation between psoriasis and cardiovascular functional indices. Angiology. 2018;69:31-37.
  • [47] Dattilo G., Borgia F., Guarneri C., Casale M., Bitto R., Morabito C., Signorelli S., Katsiki N., Cannavò S.P. Cardiovascular risk in psoriasis: current state of the art. Curr Vasc Pharmacol. 2019;17:85-91.
  • [48] Boehncke W.H. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579.
  • [49] Boehncke W.H., Boehncke S., Tobin A.M., Kirby B. The “psoriatic march”: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20:303-307.